All In Biotech

Drug Trial Radar · NCT06277219

A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

A Phase 1/2, Dose-Escalation and Cohort-Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

Last checked: Nov 19, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jun 5, 2024

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Sponsor type
Industry
First posted
Feb 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalation and Phase 2 cohort expansion.

Conditions

  • Advanced Solid Tumor

Interventions

  • LAT010Drug

    LAT010 monotherapy

  • LAT010 + ICIDrug

    LAT010 combination with PD-1 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Phase 1)Time frame: Up to 18 months
  2. Incidence of changes in clinical laboratory values (Phase 1)Time frame: Up to 15 months
  3. Incidence of dose-limiting toxicities (DLTs) (Phase 1)Time frame: The first treatment cycle (28 days) from Cycle 1 Day 1
  4. Objective response rate (ORR) per RECIST 1.1 (Phase 2)Time frame: Up to 24 months

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • D&H Cancer Research Center

    Margate, Florida · Completed

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Terminated

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Recruiting

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.